Value proposition

Improving life for cancer patients through transformative drugs

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects.

Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list.


Pharmaceuticals, Oncology, Biotech, and Clinical development